EFG International AG Buys Shares of 8,891 Gilead Sciences, Inc. $GILD

Posted by George Bondi on Aug 27th, 2026

Gilead Sciences logo EFG International AG purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 8,891 shares of the biopharmaceutical company’s stock, valued at approximately $1,123,000.

Other hedge funds also recently modified their holdings of the company. Paulson Wealth Management Inc. increased its stake in Gilead Sciences by 1.8% during the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after purchasing an additional 67 shares in the last quarter. Essex Financial Services Inc. lifted its stake in Gilead Sciences by 0.9% in the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after buying an additional 71 shares in the last quarter. Davidson Trust Co. increased its position in shares of Gilead Sciences by 4.1% during the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock worth $262,000 after acquiring an additional 74 shares in the last quarter. Alpha Cubed Investments LLC increased its position in shares of Gilead Sciences by 1.1% during the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after acquiring an additional 75 shares in the last quarter. Finally, Financial Connections Group Inc. raised its holdings in shares of Gilead Sciences by 30.2% during the first quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 76 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the sale, the chief executive officer owned 592,133 shares in the company, valued at approximately $77,160,851.23. This represents a 2.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $138.36, for a total value of $415,080.00. Following the transaction, the chief financial officer directly owned 165,646 shares of the company’s stock, valued at $22,918,780.56. This trade represents a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 87,000 shares of company stock worth $11,562,960 in the last three months. Insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD opened at $148.09 on Thursday. The stock has a market capitalization of $183.62 billion, a price-to-earnings ratio of -55.46 and a beta of 0.32. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29. The firm has a fifty day simple moving average of $133.31 and a 200 day simple moving average of $136.58. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same period in the previous year, the business earned $2.01 EPS. The company’s revenue was up 10.6% compared to the same quarter last year. Research analysts forecast that Gilead Sciences, Inc. will post -0.5 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a $0.82 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio (DPR) is presently -122.85%.

Analysts Set New Price Targets

Several equities research analysts recently commented on GILD shares. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Truist Financial dropped their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Royal Bank Of Canada lifted their price target on Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a research note on Wednesday, August 5th. Needham & Company LLC restated a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a report on Wednesday, August 5th. Finally, Daiwa Securities Group reduced their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, May 19th. Twenty-four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $158.04.

Get Our Latest Analysis on Gilead Sciences

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.